The Week

Amgen (AMGN) rose 2.2% on the week to close at $385.65, while the S&P 500 slipped 0.08%. That put the stock about 2.28 percentage points ahead of the benchmark. The five sessions started soft: a higher open on Monday faded, and Tuesday and Wednesday both closed lower, with the week’s low at $374.46. Thursday stabilised, then Friday ran up on heavy volume to the week’s high of $386.50. Friday alone accounted for more than 40% of the week’s turnover, with the full-week range at just 3.15%.

Key Events

The week’s defining story was the FDA update for Imdelltra. On Monday regulators approved a shorter monitoring window for the first two doses’ infusions, and Amgen confirmed the label change the same day. That reduces the observation burden after each dose, and the market treated it as a convenience and payer-access positive. Midweek, Bristol Myers sued Amgen over its proposed Opdivo biosimilar, which coincided with the stock underperforming peers on Tuesday. On Thursday Amgen highlighted progress on MariTide and IMDELLTRA in investor communications, and UBS initiated buy coverage. Friday brought a broad up-move that left Amgen outperforming competitors on the day.

Analyst Ratings

Thirty-three brokers cover Amgen: 7 rate it buy, 4 overweight, 18 hold, 2 underweight, and 2 sell. The consensus rating is hold, with a consensus target of $387.69, just 0.53% above the latest close of $385.65. Individual targets range from $225.00 to $457.00, so the dispersion is wide and hinges on assumptions about the late-stage pipeline. Within the biotech industry, Amgen ranks 2nd out of 501 names in analyst-rating standing, but that strength sits alongside a largely neutral consensus.

The Week Ahead

The macro calendar is busier than the company-specific one. Tuesday brings the Richmond Fed composite index, Wednesday the EIA weekly crude and Cushing inventories, and Thursday jobless claims, the current-account balance, new home sales, and EIA natural gas storage. Amgen has no scheduled earnings or major corporate events next week, so the focus shifts to market follow-through on the Imdelltra label change, any incremental news on the Bristol Myers litigation, and how the macro releases shape risk appetite.

In Short

This week’s rally overlapped with the FDA’s Imdelltra update and a fresh buy rating from UBS, but the consensus target is only 0.53% above spot, and the gap between the low and high targets is nearly 2x. That leaves most of the debate parked in the late-stage pipeline rather than current fundamentals. Valuation sits around 23.85x earnings, 17.84x book, and a 2.58% dividend yield. The latest session’s large-lot flow was net positive, but it is a single-day snapshot rather than a trend. The coming week is more about macro catalysts and the follow-through on Imdelltra and the litigation than about a company-specific event.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.